Search trials – HealthDB

Активни:

Намерени 4,781 изпитвания Стр. 210 от 240

Active (not recruiting)

The Use of DXA in Scoliosis

Scoliosis Idiopathic

This is a pilot study to look at image quality of iDXA AP supine spinal images to see if the investigators can accurately measure the size of the curve from iDXA images and to see how patients with scoliosis feel about iDXA imaging compared to normal x-rays. With normal x-rays being taken standing (or sitting if patients are in a wheelchair), it is important that the investigators understand how the lying down images compare to the standing images. Where there may be some clinical benefit, images will be taken standing (normal x-rays) and lying down (iDXA images). The investigators will see if the addition of iDXA images can help in brace design and brace monitoring.

Начало: 08.05.2024 Край: 01.06.2026 Възраст: 4–16 г.

United Kingdom Sheffield Children's NHS Foundation Trust NCT06512038

Active (not recruiting)

Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC)

Obstructive Sleep Apnea

This is a randomized controlled trial (RCT) of 4 weeks of study supplement N-acetylcysteine (NAC) versus placebo in persons with significant obstructive sleep apnea (OSA) who are receiving positive airway pressure therapy (PAP), the standard of care therapy. The purpose of the study is to determine if NAC is associated with sex-specific changes in overnight oxidative stress, inflammation, as well as endothelial dysfunction in persons with OSA.

Начало: 07.05.2024 Край: 01.05.2026 Възраст: 55–75 г.

United States NYU Langone Health NCT06311045

Active (not recruiting) Phase 3

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Atherosclerotic Cardiovascular Disease (ASCVD) Chronic Kidney Disease (CKD)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.

Начало: 30.04.2024 Край: 01.02.2029 Възраст: от 45 г. Treatment

Argentina, Australia, Austria +24 Eli Lilly and Company NCT06383390

Active (not recruiting) Phase 2

A Study Evaluating APG777 in Atopic Dermatitis

Atopic Dermatitis

This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants randomized in Part A are not permitted to participate in Part B.

Начало: 29.04.2024 Край: 01.06.2028 Възраст: от 18 г.

Canada, Czechia, France +6 Apogee Therapeutics, Inc. NCT06395948

Active (not recruiting)

Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany

Heart Diseases Cardiovascular Diseases Heart Failure

Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages. Despite advancements in treatment, a HF diagnosis still leads to significant morbidity and mortality; there is also an immense impact on patients' health-related quality of life (HRQoL). Dapagliflozin was recently granted approval for heart failure by the European Commission, regardless of ejection fraction and whether the patient has diabetes. Real-world observational data are necessary to describe dapagliflozin use in real-world settings in order to assess treatment patterns, HF symptoms and their impact on physical limitation, HRQoL and work productivity, as well as health care utilization of patients treated with dapagliflozin in this setting under local treatment standard conditions in Germany.

Начало: 25.04.2024 Край: 31.12.2026 Възраст: 18–130 г.

Germany AstraZeneca NCT06336330

Active (not recruiting) Phase 3

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)

HR+HER2- Breast Cancer

This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced, recurrent, or metastatic HR+HER2- breast cancer after failure of at least one prior line of chemotherapy.

Начало: 24.04.2024 Край: 01.05.2026 Възраст: от 18 г.

China Sichuan Baili Pharmaceutical Co., Ltd. NCT06343948

Active (not recruiting)

The UK ADAPTIS Study

Total Ankle Replacement Total Ankle Arthroplasty

An ankle replacement procedure consists of replacing the worn-out joint surfaces of the ankle with metal and plastic components that are shaped to allow continued movement of the ankle. There are several different types of ankle replacement available. Infinity ankle implants are already routinely used in NHS hospitals. The INFINITY™ with ADAPTIS™ and EVERLAST™ ankle replacement system is a development of the Infinity ankle implant, designed to attach to the bone better and to wear out more slowly. The purpose of the UK ADAPTIS™ Study is to assess the performance and function of the newly introduced INFINITY™ with ADAPTIS™ and EVERLAST™ technology Total Ankle System for total ankle replacement (TAR) or arthroplasty (TAA) and EVERLAST™ Poly Insert that modernises and streamlines Stryker's TAA/TAR portfolio. UK ADAPTIS is a prospective multi-centre cohort series of INFINITY™ with ADAPTIS™ and EVERLAST™ Technology with Poly Insert for patients requiring primary total ankle replacement (TAR) i.e. Total Ankle Arthroplasty (TAA). Patients meeting the criteria for the study will be asked to enrol by providing written informed consent. The patients will be monitored clinically by post-operative follow-up examinations and Patient reported outcome measures (PROMs) (Manchester Oxford Foot \& Ankle Questionnaire (MOXFQ), Ankle Osteoarthritis Scale (AOS), EQ5D-5L). Intended use: It is intended to give a patient limited mobility by reducing pain, restoring alignment, and replacing flexion and extension movement in the ankle joint. Indications for use: * Patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis. * Patients with a failed previous ankle surgery.

Начало: 23.04.2024 Край: 01.04.2031 Възраст: от 21 г.

United Kingdom Northumbria Healthcare NHS Foundation Trust NCT06941558

Active (not recruiting)

Zambia Healthy Choices Project for Emerging Adults Living With HIV

Pre-Exposure Prophylaxis

This project will develop and implement a multi-component intervention using mobile health technology to improve HIV self-management and reduce substance use. Specifically, the investigators will adapt Healthy Choices (HC) to develop mobile HC (mHC) and develop Motivational text messaging (MTM) for Zambian emerging adults living with HIV.

Начало: 20.04.2024 Край: 31.07.2026 Възраст: 18–24 г.

Zambia University of Massachusetts, Worcester NCT06415357

Active (not recruiting) Phase 2

Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2)

Oropharyngeal Neoplasms Robotic Surgery and/or Radiotherapy Lymphoscintigraphy

To test a new radiation treatment design based on where your cancer is located. Most participants with oropharyngeal cancer are treated with radiation to both sides of the neck. However, for participants with oropharyngeal cancer on one side of the neck, receiving radiation to both sides of the neck may result in increased side effects and radiation exposure. This study is testing the safety and effectiveness of an approach that involves radiation to only one side of the neck in an effort to reduce the overall amount of radiation given and decrease the amount of side effects you may experience.

Начало: 19.04.2024 Край: 09.12.2027 Възраст: от 18 г.

United States M.D. Anderson Cancer Center NCT06167291

Active (not recruiting) Phase 1

Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma

Neuroblastoma

MAGNETO is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and teenagers aged 1-16 years with relapsed or refractory neuroblastoma. The study will assess the feasibility of generating the ATIMP (GD2 CAR T cells) and the safety of administering the ATIMP in patients with relapsed or refractory neuroblastoma.

Начало: 19.04.2024 Край: 01.12.2041 Възраст: 1–16 г.

United Kingdom University College, London NCT05990751

Active (not recruiting) Phase 2/3

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

Dementia Moderate Dementia, Mild Alzheimer Disease

Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion. Participants who have completed the main trial will be eligible to participate in an open-label phase, which involves treatment with 10mg Xanamem once daily for a treatment period of up to a maximum of 108 weeks. The OLE is intended to finish when all participants have completed at least 60 weeks of treatment and a follow-up visit 4 weeks later.

Начало: 12.04.2024 Край: 01.02.2028 Възраст: от 50 г. Treatment

Australia, United States Actinogen Medical NCT06125951

Active (not recruiting) Phase 2/3

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Generalized Epidermolysis Bullosa Simplex

The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS.

Начало: 04.04.2024 Край: 01.03.2027 Възраст: от 6 г. Treatment

Australia, Austria, Belgium +15 TWi Biotechnology, Inc. NCT06073132

Active (not recruiting)

BCG Revaccination Study in Diabetic and Non-Diabetic Adults

Tuberculosis

The purpose of this study is to: 1. explore whether investigators can make BCG more effective by giving it in a different way. For this, aerosol inhaled BCG will be compared against the conventional BCG injection. 2. explore if there are differences in response to re-vaccination in healthy volunteers with and without Type 2 Diabetes. It will involve 36 previously BCG-vaccinated participants. Bronchoscopies will be performed 14 days post-challenge to measure BCG recovered from bronchial samples. Blood tests will be taken to look at potential immunological markers of immunity.

Начало: 03.04.2024 Край: 31.08.2028 Възраст: 18–65 г.

United Kingdom University of Oxford NCT06246851

Active (not recruiting)

Remote Therapeutic Monitoring Exercise Tracking

Parkinson Disease Multiple Sclerosis

The purpose of this study is to examine physical activity and exercise behaviors in people with Parkinson's Disease and Multiple Sclerosis over the course of 1-year using a cloud-based remote monitoring platform.

Начало: 01.04.2024 Край: 01.03.2028 Възраст: 18–89 г.

United States Shirley Ryan AbilityLab NCT06306768

Active (not recruiting) Phase 3

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

Chronic Kidney Disease and Hypertension

The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants untreated with SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or placebo/dapagliflozin; and approximately 12-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin alone. Site visits will take place at 2-, 4-, 8-, and 16- weeks following randomisation. Thereafter visits will occur approximately every 4 months, until the 24-month visit at which time baxdrostat/placebo will be discontinued. Participants will continue open-label dapagliflozin for another 12-weeks (approximately), where reassessment of eGFR will occur for the primary efficacy endpoint. In the event of premature discontinuation of blinded study intervention, participants will continue in the study and receive open-label dapagliflozin monotherapy, unless the participant meets dapagliflozin specific discontinuation criteria, in which case all study interventions will be discontinued.

Начало: 29.03.2024 Край: 24.02.2028 Възраст: от 18 г. Treatment

Argentina, Australia, Belgium +35 AstraZeneca NCT06268873

Active (not recruiting) Phase 2

Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure

HCC - Hepatocellular Carcinoma

This project is a Phase 2 trial testing the safety and efficacy of treatment with Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting in patients with BCLC A HCC treated by by percutaneous ablation (PA) procedure in a curative intent. DUMELEP is a Multicentre, Phase 2 trial Eligible patients will receive consecutively: 1. 1 Durvalumab 1500 mg/Tremelimumab 300 mg infusion in a neoadjuvant setting 2. percutaneous ablation procedure in a curative attempt at Day 30 3. 11 monthly Durvalumab 1500 mg infusions. 4. Classical follow-up during an additional year (every 3 months)

Начало: 28.03.2024 Край: 27.09.2028 Възраст: 18–85 г.

France Assistance Publique - Hôpitaux de Paris NCT06045975

Active (not recruiting) Phase 2

Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer

Colorectal Cancer (MSI-H) Colorectal Cancer (CRC)

Patients with clinical stage II-III dMMR/MSI colorectal adenocarcinoma will be treated with low-dose immunotherapy: nivolumab 100 mg or pembrolizumab 100 mg. The duration of treatment is 6 months.

Начало: 22.03.2024 Край: 31.03.2027 Възраст: от 18 г.

Russia Blokhin's Russian Cancer Research Center NCT07523763

Active (not recruiting) Phase 1

Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension

Hypertension Hypertension,Essential

This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in participants with hypertension.

Начало: 21.03.2024 Край: 31.12.2026 Възраст: 18–65 г. Treatment

Australia ADARx Pharmaceuticals, Inc. NCT06205628

Active (not recruiting) Phase 3

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)

Esophageal Squamous Cell Carcinoma

This study is a registered phase Ill, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic esophageal squamous cell carcinoma after failure of PD-1/PD-L1 monoclonal antibody in combination with platinum-based chemotherapy.

Начало: 19.03.2024 Край: 01.05.2026 Възраст: от 18 г.

China Sichuan Baili Pharmaceutical Co., Ltd. NCT06304974

Active (not recruiting)

Wishes to Improve Support and Humanity at End-of-life in Safety-net Hospitals

End of Life

Dignified and compassionate end-of-life (EOL) care is a cornerstone of high-quality, patient-centered care, but in safety-net hospitals EOL care is often overlooked, considered too late, or not at all. By eliciting and implementing final wishes for dying patients, the 3 Wishes Project (3WP) has demonstrated, in tertiary academic centers, that acts of compassion can improve the EOL experience and help families cope with loss. The investigators propose to implement the 3WP in safety-net hospitals where there are less resources and more diverse, disadvantaged patient populations, and hypothesize that there will be similar positive effects on the EOL experience for patients, families, and clinicians.

Начало: 19.03.2024 Край: 01.08.2028 Възраст: от 18 г.

United States University of California, Los Angeles NCT06277310

1 … 208 209 210 211 212 … 240